What is PURE BIOSCIENCE's earnings per share (EPS)?

PURE BIOSCIENCE (PURE) reported diluted earnings per share of -$0.02 for fiscal year 2025. This represents a 33.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

PURE BIOSCIENCE (PURE) Financials

PURE

Trailing 12 months to April 30, 2026

Revenue $2.4M +26.8% YoY

Net Income -$2.2M +21.9% YoY

EPS (Diluted) -$0.02 +33.3% YoY

Operating Cash Flow -$1.8M +17.3% YoY

Market Cap $9.8M as of Oct 19, 2026

Price / Sales 4.0x on $2.4M revenue, trailing 12 months to April 30, 2026

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to April 30, 2026

Price / Book n/m negative shareholder equity, so no book multiple, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 19, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Apr 30, 2026 Reported Jun 15, 2026 Currency USD FYE July

Newest figures come from the 10-Q for Q3 FY2026, filed Jun 15, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PURE SEC filings page.

PURE BIOSCIENCE (PURE) reported $2.4M in revenue over the twelve months to Apr 30, 2026, up 26.8% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI PURE FY2025 2026-10-04

PURE remains financing-dependent: lower overhead is narrowing losses, but operations still consume cash and equity remains negative.

Gross margin held near 59.0% from FY2024 to FY2025 while operating losses narrowed, pointing to overhead reduction rather than a major change in product economics. SG&A fell to $3.3M in FY2025, reinforcing that the improved result came mainly from the cost structure.

FY2025 operating cash outflow of $2.0M nearly matched financing inflow of $2.0M, so the improvement in net loss did not translate into self-funding operations.

FY2025 liabilities were nearly six times assets, leaving negative equity of $5.1M. A 1.1x current ratio alongside reported 2 months of liquidity indicates limited short-term balance-sheet flexibility.

Financial Health Signals

Financial health score not available

PURE BIOSCIENCE does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-187.86

PURE BIOSCIENCE scores -187.86, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($9.8M) relative to total liabilities ($6.2M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

4/8

PURE BIOSCIENCE passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality No Cash Backing

N/A

PURE BIOSCIENCE reported a net loss of $2.4M while operations used $2.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

PURE BIOSCIENCE reported an operating loss of $2.3M against $287K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$506K

YoY+3.5%

QoQ+14.2%

5Y CAGR-1.9%

10Y CAGR+2.3%

PURE BIOSCIENCE generated $506K in revenue in Q3 2026. This represents an increase of 3.5% from the same quarter a year earlier. Against the prior quarter it is up 14.2%.

Net Income

-$624K

YoY-7.6%

QoQ+20.5%

PURE BIOSCIENCE reported -$624K in net income in Q3 2026. This represents a decrease of 7.6% from the same quarter a year earlier. Against the prior quarter it is up 20.5%.

EPS (Diluted)

-$0.01

YoY0.0%

QoQ0.0%

PURE BIOSCIENCE earned -$0.01 per diluted share (EPS) in Q3 2026. That is unchanged from the same quarter a year earlier. It is unchanged from the prior quarter.

EBITDA

Not reported for Q3 2026.

Cash & Balance Sheet

Cash & Debt

$983K

YoY+82.0%

QoQ+396.5%

5Y CAGR-19.0%

10Y CAGR-15.7%

PURE BIOSCIENCE held $983K in cash as of Q3 2026; long-term debt is not reported for that period.

Shares Outstanding

130M

YoY+16.2%

QoQ+16.2%

5Y CAGR+8.3%

10Y CAGR+7.2%

PURE BIOSCIENCE had 130M shares outstanding in Q3 2026. This represents an increase of 16.2% from the same quarter a year earlier. Against the prior quarter it is up 16.2%.

Free Cash Flow

Not reported for Q3 2026.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Gross Margin

53.2%

YoY-4.7pp

QoQ-0.6pp

5Y change-3.5pp

10Y change-18.1pp

PURE BIOSCIENCE's gross margin was 53.2% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is down 4.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.6 percentage points.

Operating Margin

Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Return on Equity

Not reported for Q3 2026.

Capital Allocation

R&D Spending

$79K

YoY-13.2%

QoQ+6.8%

5Y CAGR-2.4%

10Y CAGR-9.1%

PURE BIOSCIENCE invested $79K in research and development in Q3 2026. This represents a decrease of 13.2% from the same quarter a year earlier. Against the prior quarter it is up 6.8%.

Share Buybacks

Not reported for Q3 2026.

Capital Expenditures

Not reported for Q3 2026.

PURE Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PURE quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$2.4M	$2.2M+12.4%	$2.0M+4.5%	$1.9M+3.2%	$1.8M-51.0%	$3.7M-46.5%	$6.9M+262.3%	$1.9M+7.6%	$1.8M-3.1%	$1.8M+42.0%	$1.3M+76.8%	$729K+32.5%	$550K-32.9%	$820K+1.0%	$812K+75.0%	$464K
Cost of Revenue	$997K	$899K+10.9%	$811K-10.5%	$906K+6.2%	$853K-53.9%	$1.9M-36.0%	$2.9M+297.8%	$728K-4.6%	$763K+0.4%	$760K+72.3%	$441K+54.7%	$285K-17.2%	$344K-39.1%	$565K+114.0%	$264K+101.5%	$131K
Gross Profit	$1.4M	$1.3M+13.1%	$1.2M+18.6%	$971K-2.9%	$1.0M-51.8%	$2.1M-48.4%	$4.0M+240.5%	$1.2M+16.8%	$1.0M-5.6%	$1.1M+26.3%	$848K+91.0%	$444K+115.5%	$206K-19.2%	$255K-53.5%	$548K+64.6%	$333K
R&D Expenses	$312K	$316K+4.6%	$302K+1.7%	$297K-6.9%	$319K-5.9%	$339K+5.3%	$322K-9.0%	$354K-22.9%	$459K-41.1%	$779K-16.0%	$927K+17.3%	$790K-23.4%	$1.0M-11.7%	$1.2M-37.3%	$1.9M-14.5%	$2.2M
SG&A Expenses	$3.0M	$3.3M-18.1%	$4.0M-7.5%	$4.3M+6.2%	$4.1M+0.1%	$4.0M+9.5%	$3.7M-42.4%	$6.4M+22.6%	$5.2M+0.1%	$5.2M+3.0%	$5.1M+3.3%	$4.9M-2.8%	$5.1M-1.9%	$5.2M-30.7%	$7.4M+14.1%	$6.5M
Operating Income	-$1.9M	-$2.3M+28.8%	-$3.2M+19.1%	-$3.9M-5.9%	-$3.7M-61.1%	-$2.3M-57875.0%	$4K+100.1%	-$5.6M+20.6%	-$7.0M-17.2%	-$6.0M+14.9%	-$7.1M+7.6%	-$7.6M	N/A	-$7.3M+16.2%	-$8.8M-4.6%	-$8.4M
EBITDA	N/A	-$2.3M+25.4%	-$3.0M+20.5%	-$3.8M-9.0%	-$3.5M-64.1%	-$2.1M-1191.3%	$196K+103.7%	-$5.3M+20.9%	-$6.8M-17.9%	-$5.7M+16.2%	-$6.8M+8.0%	-$7.4M	N/A	-$7.0M+16.0%	-$8.4M-6.0%	-$7.9M
Interest Expense	$377K	$287K+100.7%	$143K+921.4%	$14K+133.3%	$6K+50.0%	$4K-20.0%	$5K-16.7%	$6K-25.0%	$8K	N/A	N/A	$8K-20.0%	$10K-98.3%	$593K+311.8%	$144K	$0
Income Tax	N/A	$0	$0	$0-100.0%	$2K0.0%	$2K0.0%	$2K0.0%	$2K0.0%	$2K0.0%	$2K+3.1%	$2K0.0%	$2K	N/A	N/A	N/A	N/A
Net Income	-$2.2M	-$2.4M+28.4%	-$3.4M+15.4%	-$4.0M-13.5%	-$3.5M-50.5%	-$2.3M-58075.0%	$4K+100.1%	-$6.6M+11.9%	-$7.4M-18.8%	-$6.3M+56.4%	-$14.4M-88.4%	-$7.6M	N/A	-$7.7M+13.7%	-$8.9M-6.5%	-$8.3M
EPS (Basic)	N/A	-$0.02+33.3%	-$0.03+25.0%	-$0.040.0%	-$0.04-33.3%	-$0.03	$0.00+100.0%	-$0.09	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	-$0.02	-$0.02+33.3%	-$0.03+25.0%	-$0.040.0%	-$0.04-33.3%	-$0.03	$0.00+100.0%	-$0.09	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	112M0.0%	112M+0.4%	111M+25.4%	89M+1.9%	87M+3.0%	85M+16.1%	73M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Revenue	$506K+3.5%	$443K+13.3%	$707K+27.4%	$763K+61.7%	$489K+11.1%	$391K+20.3%	$555K-22.7%	$472K-21.6%
Cost of Revenue	$237K+13.9%	$206K+25.6%	$258K+11.7%	$296K+48.7%	$208K+13.7%	$164K+10.1%	$231K-17.5%	$199K-29.2%
Gross Profit	$269K-4.9%	$238K+4.8%	$450K+38.5%	$468K+70.2%	$283K+9.7%	$227K+28.2%	$325K-26.5%	$275K-14.3%
R&D Expenses	$79K-13.2%	$74K-8.6%	$86K+21.1%	$73K+5.8%	$91K+18.2%	$81K+6.6%	$71K-11.3%	$69K-1.4%
SG&A Expenses	$708K-8.8%	$847K-2.8%	$743K-15.7%	$731K-13.5%	$776K-22.2%	$871K-18.2%	$881K-17.9%	$845K-12.0%
Operating Income	-$518K+11.3%	-$683K+5.8%	-$379K+39.6%	-$336K+51.9%	-$584K+28.5%	-$725K+24.8%	-$627K+11.8%	-$699K+31.7%
EBITDA	N/A	N/A	-$378K	N/A	N/A	N/A	N/A	N/A
Interest Expense	$106K+35.9%	$101K+44.3%	$91K+51.7%	$79K+97.5%	$78K+90.2%	$70K+84.2%	$60K+150.0%	$40K+400.0%
Net Income	-$624K-7.6%	-$785K+1.6%	-$464K+32.7%	-$332K+56.1%	-$580K+32.3%	-$798K+20.4%	-$689K+6.3%	-$756K+26.7%
EPS (Basic)	-$0.010.0%	-$0.010.0%	$0.00+100.0%	$0.00	-$0.010.0%	-$0.010.0%	-$0.010.0%	$0.00+100.0%
EPS (Diluted)	-$0.010.0%	-$0.010.0%	$0.00+100.0%	$0.00	-$0.010.0%	-$0.010.0%	-$0.010.0%	$0.00+100.0%
Diluted Shares (Avg)	111M-0.9%	112M0.0%	112M0.0%	N/A	112M0.0%	112M0.0%	112M0.0%	N/A

Not reported in any period shown, so not listed: Income Tax.

PURE Balance Sheet

PURE quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$1.1M+29.3%	$818K-55.2%	$1.8M-59.3%	$4.5M+4.2%	$4.3M-31.9%	$6.3M+227.3%	$1.9M-25.0%	$2.6M-32.8%	$3.8M-49.4%	$7.6M+131.9%	$3.3M+75.4%	$1.9M-9.8%	$2.1M-53.7%	$4.5M-13.4%	$5.1M
Current Assets	$1.0M+30.1%	$805K-49.8%	$1.6M-58.5%	$3.9M+20.9%	$3.2M-42.6%	$5.6M+434.7%	$1.0M-28.5%	$1.5M-40.8%	$2.5M-60.0%	$6.1M+210.4%	$2.0M+314.0%	$478K-1.6%	$486K-78.4%	$2.3M-19.8%	$2.8M
Cash & Equivalents	$334K-4.3%	$349K-68.1%	$1.1M-67.7%	$3.4M+41.9%	$2.4M-37.7%	$3.8M+864.6%	$398K-53.2%	$851K-48.1%	$1.6M-68.4%	$5.2M+293.2%	$1.3M+1436.0%	$86K0.0%	$86K-90.2%	$877K-51.1%	$1.8M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$141K+151.8%	$56K-36.4%	$88K-50.8%	$179K-46.1%	$332K-39.3%	$547K+209.0%	$177K-10.2%	$197K-27.8%	$273K-22.0%	$350K+69.1%	$207K-16.9%	$249K-31.8%	$365K-44.2%	$654K-24.0%	$861K
Accounts Receivable	$474K+59.1%	$298K+4.6%	$285K+41.8%	$201K-45.4%	$368K-66.2%	$1.1M+192.0%	$373K+35.6%	$275K-7.4%	$297K+12.9%	$263K+39.2%	$189K+302.1%	$47K+161.1%	$18K-95.2%	$373K+646.0%	$50K
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$6.2M+67.7%	$3.7M+137.1%	$1.6M+170.1%	$575K-40.7%	$970K-35.8%	$1.5M+103.8%	$742K-42.7%	$1.3M-49.0%	$2.5M0.0%	$2.5M+189.2%	$878K-52.3%	$1.8M-39.7%	$3.1M-16.1%	$3.6M+286.8%	$941K
Current Liabilities	$938K+28.0%	$733K+37.8%	$532K-7.5%	$575K-40.7%	$970K-35.8%	$1.5M+104.9%	$738K-42.4%	$1.3M-49.3%	$2.5M-0.3%	$2.5M+191.8%	$869K-52.5%	$1.8M-15.0%	$2.2M-40.8%	$3.6M+289.0%	$935K
Non-Current Liabilities	$5.2M+77.6%	$2.9M+188.8%	$1.0M	$0	$0	$0-100.0%	$4K-69.2%	$13K+18.2%	$11K+266.7%	$3K-66.7%	$9K-30.8%	$13K-98.6%	$900K+29900.0%	$3K-50.0%	$6K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0-100.0%	$1.3M	N/A	N/A
Total Equity	-$5.1M-78.6%	-$2.9M-1152.9%	$272K-93.0%	$3.9M+17.3%	$3.3M-30.7%	$4.8M+304.3%	$1.2M-7.1%	$1.3M-0.7%	$1.3M-74.3%	$5.0M+110.8%	$2.4M+13917.6%	$17K+101.7%	-$991K-221.1%	$818K-80.6%	$4.2M
Retained Earnings	-$139.0M-1.8%	-$136.6M-2.5%	-$133.2M-3.1%	-$129.3M-2.8%	-$125.8M-1.9%	-$123.5M0.0%	-$123.5M-5.6%	-$116.9M-6.8%	-$109.5M-6.1%	-$103.2M-16.2%	-$88.8M-9.4%	-$81.2M-15.7%	-$70.2M-12.3%	-$62.5M-16.6%	-$53.6M

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Total Assets	$1.6M+47.4%	$788K+37.3%	$1.2M+28.4%	$1.1M+29.3%	$1.1M+14.9%	$574K-47.1%	$924K-58.9%	$818K-55.2%
Current Assets	$1.5M+48.1%	$779K+38.6%	$1.2M+29.1%	$1.0M+30.1%	$1.0M+20.4%	$562K-40.1%	$911K-55.9%	$805K-49.8%
Cash & Equivalents	$983K+82.0%	$198K-2.0%	$434K+25.4%	$334K-4.3%	$540K+22.2%	$202K-63.7%	$346K-76.0%	$349K-68.1%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$232K+77.1%	$244K+225.3%	$237K+229.2%	$141K+151.8%	$131K+77.0%	$75K+1.4%	$72K-30.8%	$56K-36.4%
Accounts Receivable	$242K-15.7%	$252K+40.0%	$389K+4.9%	$474K+59.1%	$287K+22.6%	$180K+5.3%	$371K+6.9%	$298K+4.6%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$7.4M+26.0%	$7.1M+45.9%	$6.7M+52.3%	$6.2M+67.7%	$5.9M+91.5%	$4.8M+101.1%	$4.4M+67.9%	$3.7M+137.1%
Current Liabilities	$3.7M+275.9%	$3.1M+252.8%	$3.2M+246.8%	$938K+28.0%	$972K+45.9%	$866K+58.9%	$911K+13.0%	$733K+37.8%
Non-Current Liabilities	$3.7M-23.6%	$4.0M+0.8%	$3.6M+1.8%	$5.2M+77.6%	$4.9M+104.1%	$4.0M+113.5%	$3.5M+92.1%	$2.9M+188.8%
Total Equity	-$5.8M-21.3%	-$6.3M-47.0%	-$5.5M-58.6%	-$5.1M-78.6%	-$4.8M-124.3%	-$4.3M-223.0%	-$3.5M-812.8%	-$2.9M-1152.9%
Retained Earnings	-$140.9M-1.6%	-$140.2M-1.6%	-$139.5M-1.6%	-$139.0M-1.8%	-$138.7M-2.1%	-$138.1M-2.3%	-$137.3M-2.5%	-$136.6M-2.5%

Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.

PURE Cash Flow Statement

PURE quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	-$1.8M	-$2.0M+20.4%	-$2.5M+22.8%	-$3.3M-35.6%	-$2.4M-107.2%	-$1.2M-274.4%	$669K+122.4%	-$3.0M+23.1%	-$3.9M+14.8%	-$4.6M+8.6%	-$5.0M+17.7%	-$6.1M+4.2%	-$6.3M-62.0%	-$3.9M+30.1%	-$5.6M+8.8%	-$6.1M
Depreciation & Amortization	N/A	$2K-98.6%	$148K+26.5%	$117K-45.1%	$213K+23.8%	$172K-10.4%	$192K-20.3%	$241K-15.4%	$285K+3.3%	$276K+26.0%	$219K+6.3%	$206K-16.9%	$248K-20.3%	$311K-19.2%	$385K-18.3%	$471K
Stock-Based Compensation	N/A	$147K-31.3%	$214K-34.0%	$324K-42.9%	$567K-32.6%	$841K+6.9%	$787K-67.9%	$2.4M+3.8%	$2.4M+120.5%	$1.1M-43.7%	$1.9M-20.2%	$2.4M-19.5%	$3.0M+310.8%	$720K-33.1%	$1.1M-9.8%	$1.2M
Capital Expenditures	N/A	N/A	N/A	$33K-59.3%	$81K-84.5%	$521K+798.3%	$58K+728.6%	$7K-63.2%	$19K-90.8%	$206K-47.2%	$390K+381.5%	$81K+285.7%	$21K+75.0%	$12K+20.0%	$10K-28.6%	$14K
Free Cash Flow	N/A	N/A	N/A	-$3.3M-32.5%	-$2.5M-48.0%	-$1.7M-376.3%	$611K+120.4%	-$3.0M+23.3%	-$3.9M+18.1%	-$4.8M+11.4%	-$5.4M+12.4%	-$6.1M+3.2%	-$6.3M-62.1%	-$3.9M+30.0%	-$5.6M+8.8%	-$6.1M
Investing Cash Flow	N/A	N/A	N/A	-$33K+59.3%	-$81K+84.5%	-$521K-798.3%	-$58K-346.2%	-$13K+61.8%	-$34K+85.0%	-$226K+44.2%	-$405K-278.5%	-$107K-132.6%	-$46K+80.1%	-$231K+7.2%	-$249K-2.0%	-$244K
Financing Cash Flow	$2.2M	$2.0M+12.0%	$1.8M+75.9%	$1.0M-71.0%	$3.5M+1364.4%	$239K-91.6%	$2.8M+11.0%	$2.5M-18.6%	$3.1M+153.8%	$1.2M-86.7%	$9.3M+25.2%	$7.4M+15.2%	$6.4M+95.3%	$3.3M-33.1%	$4.9M-17.6%	$6.0M

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Operating Cash Flow	-$468K+8.6%	-$606K-11.4%	-$250K+50.3%	-$456K+23.1%	-$512K+16.7%	-$544K+38.4%	-$503K-14.3%	-$593K+20.3%
Depreciation & Amortization	N/A	N/A	$1K	N/A	N/A	N/A	N/A	N/A
Stock-Based Compensation	$55K+66.7%	$58K+114.8%	$34K-40.4%	N/A	$33K	$27K	$57K-28.7%	N/A
Financing Cash Flow	$1.3M+47.4%	$370K-7.5%	$350K-30.0%	$250K-50.0%	$850K+70.0%	$400K	$500K-36.3%	$500K

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.

PURE Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PURE quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	59.3%+0.3pp	58.9%+7.0pp	51.9%-3.3pp	55.2%-1.0pp	56.1%-2.0pp	58.1%-3.7pp	61.9%+4.9pp	57.0%-1.5pp	58.5%-7.3pp	65.8%+4.9pp	60.9%+23.5pp	37.5%+6.3pp	31.1%-36.4pp	67.5%-4.3pp	71.8%
Operating Margin	-103.4%	-163.2%	-210.7%	-205.4%	-62.5%-62.6pp	0.1%	-292.8%	-397.0%	-328.1%	-547.5%	-1048.0%	N/A	-895.0%	-1078.1%	-1803.2%
Net Margin	-109.1%	-171.4%	-211.7%	-192.6%	-62.7%-62.8pp	0.1%	-343.3%	-419.5%	-342.1%	-1114.9%	-1046.2%	N/A	-935.5%	-1094.8%	-1799.4%
Return on Equity	N/A	N/A	-1456.3%-1366.9pp	-89.3%-19.7pp	-69.6%-69.7pp	0.1%+550.8pp	-550.8%+30.2pp	-581.0%-95.4pp	-485.5%-199.4pp	-286.1%+34.0pp	-320.1%	N/A	N/A	-1086.8%-888.4pp	-198.4%
Return on Assets	-226.8%+182.8pp	-409.5%-192.5pp	-217.0%-139.2pp	-77.8%-24.0pp	-53.9%-54.0pp	0.1%+339.3pp	-339.2%-50.2pp	-289.0%-125.4pp	-163.6%+26.5pp	-190.0%+43.9pp	-233.9%	N/A	-372.0%-172.6pp	-199.4%-37.2pp	-162.2%
Current Ratio	1.120.0x	1.10-1.9x	3.02-3.7x	6.72+3.4x	3.30-0.4x	3.68+2.3x	1.41+0.3x	1.14+0.2x	0.97-1.4x	2.42+0.1x	2.28+2.0x	0.260.0x	0.23-0.4x	0.62-2.4x	3.00
Debt-to-Equity	N/A	N/A	5.71+5.6x	0.15-0.1x	0.290.0x	0.31-0.3x	0.62-0.4x	1.01-1.0x	1.97+1.5x	0.51+0.5x	0.000.0x	0.00	N/A	4.45+4.2x	0.22
Asset Turnover	2.08-0.3x	2.39+1.4x	1.03+0.6x	0.40-0.5x	0.86-0.2x	1.09+0.1x	0.99+0.3x	0.69+0.2x	0.48+0.3x	0.17-0.1x	0.22-0.1x	0.30-0.1x	0.40+0.2x	0.18+0.1x	0.09
FCF Margin	N/A	N/A	-177.0%	-137.8%	-45.6%-54.5pp	8.8%	-157.0%	-220.2%	-260.4%	-417.5%	-842.8%	-1154.0%	-477.6%	-689.4%	-1322.8%

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Gross Margin	53.2%-4.7pp	53.7%-4.3pp	63.6%+5.1pp	61.3%+3.1pp	57.9%-0.8pp	58.1%+3.6pp	58.6%-3.0pp	58.3%+4.9pp
Operating Margin	-102.4%	-154.2%	-53.6%	-44.0%	-119.4%	-185.4%	-113.0%	-148.1%
Net Margin	-123.3%	-177.2%	-65.6%	-43.5%	-118.6%	-204.1%	-124.1%	-160.2%
Return on Assets	-40.1%+14.8pp	-99.6%+39.4pp	-39.1%+35.5pp	-31.4%+61.0pp	-54.9%+38.3pp	-139.0%-46.8pp	-74.6%-41.9pp	-92.4%-35.9pp
Current Ratio	0.42-0.7x	0.26-0.4x	0.37-0.6x	1.120.0x	1.08-0.2x	0.65-1.1x	1.00-1.6x	1.10-1.9x
Asset Turnover	0.32-0.1x	0.56-0.1x	0.600.0x	0.72+0.1x	0.460.0x	0.68+0.4x	0.60+0.3x	0.58+0.2x

Not reported in any period shown, so not listed: Return on Equity, Debt-to-Equity, FCF Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.

Note: Shareholder equity is negative (-$5.1M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
PURE BIOSCIENCE PURE	FY2025	$2.2M	-$2.4M	N/A	$9.8M	—
SENTIENT BRANDS HLDGS INC SNBH	FY2025	$701K	-$1.2M	N/A	$1.3M	—
SKINVISIBLE INC SKVI	FY2025	$20K	N/A	N/A	$843K	—
BEMAX INC BMXC	FY2017	$145K	-$1.6M	N/A	$5.2M	—

Where PURE BIOSCIENCE Ranks

Frequently Asked Questions

What is PURE BIOSCIENCE's annual revenue?

PURE BIOSCIENCE (PURE) reported $2.2M in total revenue for fiscal year 2025. This represents a 12.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is PURE BIOSCIENCE's revenue growing?

PURE BIOSCIENCE (PURE) revenue grew by 12.4% year-over-year, from $2.0M to $2.2M in fiscal year 2025.

Is PURE BIOSCIENCE profitable?

No, PURE BIOSCIENCE (PURE) reported a net income of -$2.4M in fiscal year 2025.

What is PURE BIOSCIENCE's EBITDA?

PURE BIOSCIENCE (PURE) had EBITDA of -$2.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is PURE BIOSCIENCE's gross margin?

PURE BIOSCIENCE (PURE) had a gross margin of 59.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is PURE BIOSCIENCE's operating cash flow?

PURE BIOSCIENCE (PURE) recorded an outflow of $2.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are PURE BIOSCIENCE's total assets?

PURE BIOSCIENCE (PURE) had $1.1M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does PURE BIOSCIENCE spend on research and development?

PURE BIOSCIENCE (PURE) invested $316K in research and development during fiscal year 2025.

How many shares does PURE BIOSCIENCE have outstanding?

PURE BIOSCIENCE (PURE) had 112M shares outstanding as of fiscal year 2025.

What is PURE BIOSCIENCE's current ratio?

PURE BIOSCIENCE (PURE) had a current ratio of 1.12 as of fiscal year 2025, which is considered adequate.

What is PURE BIOSCIENCE's return on assets (ROA)?

PURE BIOSCIENCE (PURE) had a return on assets of -226.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is PURE BIOSCIENCE's P/E ratio?

PURE BIOSCIENCE (PURE) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to April 30, 2026). The market capitalization is $9.8M as of Oct 19, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is PURE BIOSCIENCE's price-to-sales ratio?

PURE BIOSCIENCE (PURE) trades at 4.0x sales, its market capitalization divided by revenue of $2.4M revenue, trailing 12 months to April 30, 2026. The market capitalization is $9.8M as of Oct 19, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does PURE BIOSCIENCE's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, PURE BIOSCIENCE (PURE) held $334K in cash, cash equivalents and investments, and reported an operating cash outflow of $2.0M over that year. Dividing the one by the other, the reported balance equals about 2 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Why is PURE BIOSCIENCE's debt-to-equity ratio negative or not reported?

PURE BIOSCIENCE (PURE) has negative shareholder equity of -$5.1M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is PURE BIOSCIENCE's Altman Z-Score?

PURE BIOSCIENCE (PURE) has an Altman Z-Score of -187.86, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is PURE BIOSCIENCE's Piotroski F-Score?

PURE BIOSCIENCE (PURE) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are PURE BIOSCIENCE's earnings high quality?

PURE BIOSCIENCE (PURE) reported a net loss of $2.4M while operations used $2.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can PURE BIOSCIENCE cover its interest payments?

PURE BIOSCIENCE (PURE) reported an operating loss of $2.3M against $287K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.